Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270770 | 0.93 | PDE4B (0.50) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4270778 | 0.93 | PDE4B (0.50) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3164585 | 0.90 | GPR119 (0.51) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4282199 | 0.88 | PDE4B (0.49) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL7727287 | 0.84 | NPBWR1 (0.57) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3100314 | 0.84 | GPR119 (0.52) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL14453583 | 0.84 | NPBWR1 (0.57) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4270782 | 0.82 | PDE4B (0.50) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4270774 | 0.82 | PDE4B (0.50) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL15014299 | 0.81 | PDE4B (0.46) | GPR119PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1644334-B1 | ANTITHROMBOTIC ETHERS | LILLY CO ELI (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1644334-A1 | ANTITHROMBOTIC ETHERS | Eli Lilly and Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004108677-A1 | ANTITHROMBOTIC ETHERS | ELI LILLY AND COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108594-A1 | Antithrombotic Ethers | F11, SERPINC1, F2 | GPR119 1289/4885PDE4B 2222/4885PDE4D 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.